Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II. J of Skin. 2025;9(6):s707. doi:10.25251/fpf9fe87